ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NRSN NeuroSense Therapeutics Ltd

1.83
0.10 (5.78%)
Last Updated: 12:46:23
Delayed by 15 minutes

Period:

Draw Mode:

Volume 74,637
Bid Price 1.81
Ask Price 1.85
News -
Day High 1.85

Low
0.40

52 Week Range

High
2.33

Day Low 1.73
Company Name Stock Ticker Symbol Market Type
NeuroSense Therapeutics Ltd NRSN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 5.78% 1.83 12:46:23
Open Price Low Price High Price Close Price Prev Close
1.73 1.73 1.85 1.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
219 74,637 $ 1.79 $ 133,641 - 0.40 - 2.33
Last Trade Time Type Quantity Stock Price Currency
12:48:49 37 $ 1.83 USD

NeuroSense Therapeutics Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.24M 11.79M - 0 -12.34M -1.05 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NeuroSense Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No NRSN Message Board. Create One! See More Posts on NRSN Message Board See More Message Board Posts

Historical NRSN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.811.88991.451.77133,4990.021.10%
1 Month1.862.331.311.83291,887-0.03-1.61%
3 Months0.812.330.7611.50308,0981.02125.93%
6 Months0.782.330.401.07585,6741.05134.62%
1 Year1.642.330.401.11319,2190.1911.59%
3 Years4.558.180.403.561,204,684-2.72-59.78%
5 Years4.558.180.403.561,204,684-2.72-59.78%

NeuroSense Therapeutics Description

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Your Recent History

Delayed Upgrade Clock